{"id":8616,"date":"2013-07-17T06:38:02","date_gmt":"2013-07-17T10:38:02","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=8616"},"modified":"2013-07-17T06:38:42","modified_gmt":"2013-07-17T10:38:42","slug":"nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616","title":{"rendered":"Nymox Pharmaceutical Corporation (NASDAQ:NYMX) shares gained by 6.4%"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 07\/17\/2013 (wallstreetpr) &#8211; Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced favorable results from the recent review of Safety Monitoring Committee on the safety data in the study \u201cNX02-0017\u201d in one of the two ongoing phase 3 pivotal studies of \u201cNX-1207\u201d that is currently in the company\u2019s pipeline for benign prostatic hyperplasia. The Safety Monitoring Committee on July 9<sup>th<\/sup>, 2013 found no safety concerns till date. The phase 3 studies have completed recruitment of patients and treatment with a single intra-prostatic injection of drug or placebo and the evaluation of patients is currently ongoing at more than 70 clinical trial sites across US.<\/p>\n<p style=\"text-align: justify;\">The phase 3 development of NX-1207 for the treatment of BPH is currently undertaken by the company with the sponsorship from Recordati S.p.A., which is Nymox\u2019s European licensing partner. NX-1207 is a novel and patented therapeutic agent of Nymox Pharmaceutical and is directly administered into the prostate in an office setting by an efficient urologist. As there is no requirement for anaesthesia, sedation and catheterization, there will be lesser discomfort and until now, there were no adverse side effects reported during the treatment and evaluation.<\/p>\n<p style=\"text-align: justify;\">During the last trading session, Nymox Pharmaceuticals was trading at the value of $16.428 with an increase of 6.4% during after-hours with the total number of 5400 shares traded. The rate of trading was 6.72% above the company\u2019s moving average in the past 50 days and was 19.48% above the company\u2019s moving average for the past 200 days. This rate is found to be 21.54% lower than its 52-week high and 55.96% higher to its 52-week low. The PE ration for the rate of trading was 73.52 and the market capitalization of the company was $1.548.<\/p>\n<p style=\"text-align: justify;\">Nymox Pharmaceuticals is a biopharmaceutical company that is currently involved in the research and development of drugs and diagnostics mainly for brain disorders and diseases of the aged people. The emphasis of this development is primarily on Alzheimer&#8217;s disease.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 07\/17\/2013 (wallstreetpr) &#8211; Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced favorable results from the recent review of Safety Monitoring Committee on the safety data [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":8650,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2905,2904],"stock_ticker":[],"class_list":["post-8616","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nasdaqnymx","tag-nymox-pharmaceutical-corporation-nasdaq-nymx","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nymox Pharmaceutical Corporation (NASDAQ:NYMX) shares gained by 6.4% - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nymox Pharmaceutical Corporation (NASDAQ:NYMX) shares gained by 6.4% - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 07\/17\/2013 (wallstreetpr) &#8211; Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced favorable results from the recent review of Safety Monitoring Committee on the safety data [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2013-07-17T10:38:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2013-07-17T10:38:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/Pharmaceutical-Vials.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"Nymox Pharmaceutical Corporation (NASDAQ:NYMX) shares gained by 6.4%\",\"datePublished\":\"2013-07-17T10:38:02+00:00\",\"dateModified\":\"2013-07-17T10:38:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616\"},\"wordCount\":321,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/Pharmaceutical-Vials.jpg\",\"keywords\":[\"NASDAQ:NYMX\",\"Nymox Pharmaceutical Corporation (NASDAQ: NYMX)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616\",\"name\":\"Nymox Pharmaceutical Corporation (NASDAQ:NYMX) shares gained by 6.4% - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/Pharmaceutical-Vials.jpg\",\"datePublished\":\"2013-07-17T10:38:02+00:00\",\"dateModified\":\"2013-07-17T10:38:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/Pharmaceutical-Vials.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/Pharmaceutical-Vials.jpg\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nymox Pharmaceutical Corporation (NASDAQ:NYMX) shares gained by 6.4%\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nymox Pharmaceutical Corporation (NASDAQ:NYMX) shares gained by 6.4% - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616","og_locale":"en_US","og_type":"article","og_title":"Nymox Pharmaceutical Corporation (NASDAQ:NYMX) shares gained by 6.4% - Wall Street PR","og_description":"Boston, MA 07\/17\/2013 (wallstreetpr) &#8211; Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced favorable results from the recent review of Safety Monitoring Committee on the safety data [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2013-07-17T10:38:02+00:00","article_modified_time":"2013-07-17T10:38:42+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/Pharmaceutical-Vials.jpg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"Nymox Pharmaceutical Corporation (NASDAQ:NYMX) shares gained by 6.4%","datePublished":"2013-07-17T10:38:02+00:00","dateModified":"2013-07-17T10:38:42+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616"},"wordCount":321,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/Pharmaceutical-Vials.jpg","keywords":["NASDAQ:NYMX","Nymox Pharmaceutical Corporation (NASDAQ: NYMX)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616","url":"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616","name":"Nymox Pharmaceutical Corporation (NASDAQ:NYMX) shares gained by 6.4% - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/Pharmaceutical-Vials.jpg","datePublished":"2013-07-17T10:38:02+00:00","dateModified":"2013-07-17T10:38:42+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/Pharmaceutical-Vials.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/Pharmaceutical-Vials.jpg","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nymox-pharmaceutical-corporation-nasdaqnymx-shares-gained-by-6-4-8616#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Nymox Pharmaceutical Corporation (NASDAQ:NYMX) shares gained by 6.4%"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/8616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=8616"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/8616\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/8650"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=8616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=8616"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=8616"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=8616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}